These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29058180)

  • 1. Studying KCNQ1 Mutation and Drug Response in Type 1 Long QT Syndrome Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Wei H; Wu J; Liu Z
    Methods Mol Biol; 2018; 1684():7-28. PubMed ID: 29058180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation.
    Wuriyanghai Y; Makiyama T; Sasaki K; Kamakura T; Yamamoto Y; Hayano M; Harita T; Nishiuchi S; Chen J; Kohjitani H; Hirose S; Yokoi F; Gao J; Chonabayashi K; Watanabe K; Ohno S; Yoshida Y; Kimura T; Horie M
    Heart Rhythm; 2018 Oct; 15(10):1566-1574. PubMed ID: 29857160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Ma D; Wei H; Lu J; Huang D; Liu Z; Loh LJ; Islam O; Liew R; Shim W; Cook SA
    Stem Cell Res Ther; 2015 Mar; 6(1):39. PubMed ID: 25889101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation.
    Mura M; Lee YK; Pisano F; Ginevrino M; Boni M; Calabrò F; Crotti L; Valente EM; Schwartz PJ; Tse HF; Gnecchi M
    Stem Cell Res; 2019 May; 37():101431. PubMed ID: 30974404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation.
    Mura M; Lee YK; Pisano F; Ginevrino M; Boni M; Calabrò F; Crotti L; Valente EM; Schwartz PJ; Tse HF; Gnecchi M
    Stem Cell Res; 2019 May; 37():101437. PubMed ID: 31009818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
    Moretti A; Bellin M; Welling A; Jung CB; Lam JT; Bott-Flügel L; Dorn T; Goedel A; Höhnke C; Hofmann F; Seyfarth M; Sinnecker D; Schömig A; Laugwitz KL
    N Engl J Med; 2010 Oct; 363(15):1397-409. PubMed ID: 20660394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease characterization using LQTS-specific induced pluripotent stem cells.
    Egashira T; Yuasa S; Suzuki T; Aizawa Y; Yamakawa H; Matsuhashi T; Ohno Y; Tohyama S; Okata S; Seki T; Kuroda Y; Yae K; Hashimoto H; Tanaka T; Hattori F; Sato T; Miyoshi S; Takatsuki S; Murata M; Kurokawa J; Furukawa T; Makita N; Aiba T; Shimizu W; Horie M; Kamiya K; Kodama I; Ogawa S; Fukuda K
    Cardiovasc Res; 2012 Sep; 95(4):419-29. PubMed ID: 22739119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression-Replacement
    Dotzler SM; Kim CSJ; Gendron WAC; Zhou W; Ye D; Bos JM; Tester DJ; Barry MA; Ackerman MJ
    Circulation; 2021 Apr; 143(14):1411-1425. PubMed ID: 33504163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of eight human induced pluripotent stem cell (iPSC) lines from familial Long QT Syndrome type 1 (LQT1) patients carrying KCNQ1 c.1697C>A mutation (NUIGi005-A, NUIGi005-B, NUIGi005-C, NUIGi006-A, NUIGi006-B, NUIGi006-C, NUIGi007-A, and NUIGi007-B).
    Ge N; Liu M; Krawczyk J; McInerney V; Galvin J; Shen S; O'Brien T; Prendiville T
    Stem Cell Res; 2019 Aug; 39():101502. PubMed ID: 31415974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of the human induced pluripotent stem cell (hiPSC) line NCUFi001-A from a patient carrying KCNQ1 G314S mutation.
    Lavra L; Magi F; Ulivieri A; Morgante A; Paulis M; Sala L; Pedrazzini M; Polisca P; Rocchetti M; Calò L; Sciacchitano S; Salehi LB
    Stem Cell Res; 2021 Jul; 54():102418. PubMed ID: 34130155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of twelve human induced pluripotent stem cell (iPSC) lines from four familial long QT syndrome type 1 (LQT1) patients carrying KCNQ1 c.1201dupC mutation.
    Ge N; Liu M; Ding Y; Krawczyk J; McInerney V; Galvin J; Shen S; Prendiville T; O'Brien T
    Stem Cell Res; 2019 Dec; 41():101650. PubMed ID: 31765965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
    Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
    Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene.
    Mura M; Pisano F; Stefanello M; Ginevrino M; Boni M; Calabrò F; Crotti L; Valente EM; Schwartz PJ; Brink PA; Gnecchi M
    Stem Cell Res; 2019 Apr; 36():101416. PubMed ID: 30878014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue.
    Zhang M; D'Aniello C; Verkerk AO; Wrobel E; Frank S; Ward-van Oostwaard D; Piccini I; Freund C; Rao J; Seebohm G; Atsma DE; Schulze-Bahr E; Mummery CL; Greber B; Bellin M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5383-92. PubMed ID: 25453094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
    Jouni M; Si-Tayeb K; Es-Salah-Lamoureux Z; Latypova X; Champon B; Caillaud A; Rungoat A; Charpentier F; Loussouarn G; Baró I; Zibara K; Lemarchand P; Gaborit N
    J Am Heart Assoc; 2015 Sep; 4(9):e002159. PubMed ID: 26330336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis.
    Ronchi C; Bernardi J; Mura M; Stefanello M; Badone B; Rocchetti M; Crotti L; Brink P; Schwartz PJ; Gnecchi M; Zaza A
    Cardiovasc Res; 2021 Jan; 117(2):472-483. PubMed ID: 32061134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment.
    Wang F; Han Y; Sang W; Wang L; Liang X; Wang L; Xing Q; Guo Y; Zhang J; Zhang L; Zukela T; Xiaokereti J; Lu Y; Zhou X; Tang B; Li Y
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A computational model of induced pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of KCNQ1 genetic variants.
    Kernik DC; Yang PC; Kurokawa J; Wu JC; Clancy CE
    PLoS Comput Biol; 2020 Aug; 16(8):e1008109. PubMed ID: 32797034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.